BORIANI, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 103.644
EU - Europa 56.725
AS - Asia 44.005
SA - Sud America 7.895
AF - Africa 901
OC - Oceania 393
Continente sconosciuto - Info sul continente non disponibili 63
Totale 213.626
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 102.012
SE - Svezia 21.003
SG - Singapore 14.138
GB - Regno Unito 10.991
CN - Cina 10.789
IT - Italia 6.711
BR - Brasile 6.520
HK - Hong Kong 6.339
VN - Vietnam 4.576
DE - Germania 3.417
FI - Finlandia 3.166
PL - Polonia 3.161
TR - Turchia 2.080
UA - Ucraina 1.910
RU - Federazione Russa 1.681
FR - Francia 1.632
KR - Corea 1.194
BG - Bulgaria 887
BD - Bangladesh 873
IN - India 748
ID - Indonesia 606
CA - Canada 552
NL - Olanda 496
AR - Argentina 463
JP - Giappone 463
BZ - Belize 402
MX - Messico 386
AU - Australia 371
IQ - Iraq 364
ES - Italia 264
AE - Emirati Arabi Uniti 261
IE - Irlanda 261
AT - Austria 252
PK - Pakistan 239
ZA - Sudafrica 225
EC - Ecuador 189
CO - Colombia 185
UZ - Uzbekistan 154
VE - Venezuela 153
MA - Marocco 148
CL - Cile 127
LT - Lituania 112
MY - Malesia 103
PH - Filippine 103
CZ - Repubblica Ceca 102
SA - Arabia Saudita 102
JO - Giordania 98
EG - Egitto 95
KE - Kenya 94
BE - Belgio 92
TN - Tunisia 81
NP - Nepal 80
AZ - Azerbaigian 78
RO - Romania 76
CH - Svizzera 74
DZ - Algeria 73
PY - Paraguay 71
TH - Thailandia 70
TW - Taiwan 69
IL - Israele 66
BO - Bolivia 64
PE - Perù 60
UY - Uruguay 59
JM - Giamaica 58
KZ - Kazakistan 52
PT - Portogallo 48
RS - Serbia 48
GE - Georgia 46
DO - Repubblica Dominicana 45
IR - Iran 45
GR - Grecia 44
CR - Costa Rica 40
OM - Oman 39
BY - Bielorussia 36
EU - Europa 36
AL - Albania 33
HR - Croazia 32
DK - Danimarca 31
SN - Senegal 30
TT - Trinidad e Tobago 29
LB - Libano 28
PA - Panama 27
KG - Kirghizistan 26
ET - Etiopia 25
BH - Bahrain 24
HU - Ungheria 23
PS - Palestinian Territory 23
QA - Qatar 23
SI - Slovenia 22
SK - Slovacchia (Repubblica Slovacca) 21
BA - Bosnia-Erzegovina 19
MD - Moldavia 19
AO - Angola 18
NG - Nigeria 18
NZ - Nuova Zelanda 18
NO - Norvegia 17
CY - Cipro 16
CI - Costa d'Avorio 14
HN - Honduras 14
AM - Armenia 13
Totale 213.311
Salva come PNG Salva come JPEG
Città #
Stockholm 18.326
Fairfield 12.855
Ashburn 10.179
Singapore 9.174
Woodbridge 7.524
Santa Clara 7.371
Southend 7.258
Hong Kong 6.175
Houston 5.913
Seattle 4.995
Cambridge 4.158
Wilmington 4.146
Chandler 4.145
Jacksonville 3.669
San Jose 3.593
Hefei 3.258
Warsaw 3.010
Helsinki 2.824
Ann Arbor 2.816
London 2.610
Dearborn 2.335
Beijing 2.057
New York 1.720
The Dalles 1.703
Modena 1.512
Nyköping 1.463
Ho Chi Minh City 1.400
San Diego 1.257
Izmir 1.225
Los Angeles 1.183
Seoul 1.150
Chicago 1.139
Hanoi 1.134
Council Bluffs 1.078
Princeton 893
Sofia 863
Lauterbourg 792
Dallas 762
Eugene 730
Milan 690
Buffalo 564
Moscow 534
São Paulo 526
Jakarta 478
Shanghai 444
Columbus 431
Belize City 400
Salt Lake City 375
Boardman 351
Rome 315
Atlanta 308
Tokyo 301
Bologna 297
Munich 271
Da Nang 266
Falls Church 257
Dublin 235
Frankfurt am Main 224
Nuremberg 216
Haiphong 211
Rio de Janeiro 211
Amsterdam 202
Redondo Beach 190
Fremont 189
Guangzhou 176
Toronto 171
Perth 170
Las Vegas 169
Saint Louis 169
Norwalk 163
Belo Horizonte 153
Kent 150
Orem 147
Lappeenranta 145
Albuquerque 139
Tampa 139
Tashkent 139
Phoenix 137
Elk Grove Village 134
Baghdad 132
Kunming 132
Brooklyn 131
Nanjing 120
Redwood City 120
Johannesburg 119
Naples 116
Mexico City 111
Brasília 107
Curitiba 104
Kilburn 100
Montreal 100
Miano 99
Vienna 99
Philadelphia 96
San Francisco 96
Amman 94
Dhaka 93
Paris 87
Florence 86
Miami 86
Totale 161.410
Salva come PNG Salva come JPEG
Nome #
'Pill-in-the-pocket' treatment for recent-onset atrial fibrillation [4] 2.648
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 2.477
'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: The EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry 2.458
'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase 2.411
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA) 2.154
12-year Temporal Trend in Referral Pattern and Test Results of Stress Echocardiography in a Tertiary Care Referral Center with Moderate Volume Activities and Cath-lab Facility 2.094
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 2.091
11C-mHED for PET / CT: principles of synthesis, methodology and first clinical applications 2.075
108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. 2.074
'Real-World' antithrombotic treatment in atrial fibrillation: The eorp-af pilot survey 2.072
Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regurgitation 702
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing 649
2018 EHRA expert consensus statement on lead extraction: Recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: Endorsed by APHRS/HRS/LAHRS 597
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) 579
A changing scenario in the clinical use of implantable defibrillators: the need for long-term data on lead performance. 534
La sindrome da pacemaker. 525
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC (Eur Heart J (2021) 42 (373–498) DOI: 10.1093/eurheartj/ehaa612) 516
Atrial Fibrillation in the Setting of Acute Pneumonia: Not a Secondary Arrhythmia 489
Linee guida AIAC all'impianto di pacemaker, dispositivi per la resincronizzazione cardiaca, defibrillatori automatici e loop recorder. Update 2011. 484
Screening for atrial fibrillation: A Report of the AF-SCREEN International Collaboration 478
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) 448
A prospective randomized evaluation of VV delay optimization in CRT patients. Proceedings 16th World Congress in Cardiac Electrophysiology and Cardiac Techniques 434
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation 420
Registro Italiano Pacemaker e Defibrillatori: Bollettino Periodico 2016 Associazione Italiana di Aritmologia e Cardiostimolazione 398
The future of continuing medical education: the roles of medical professional societies and the health care industry: Position paper prepared with contributions from the European Society of Cardiology Committees for Advocacy, Education and Industry Relations, Endorsed by the Board of the European Society of Cardiology 380
Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol 356
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) 347
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial 344
Prevalence and clinical significance of left bundle branch block according to classical or strict definition criteria in permanent pacemaker patients 344
Guía de práctica clínica de la ESC 2013 sobre estimulación cardiaca y terapia de resincronización cardiaca 338
Home care for heart failure: can caregiver education prevent hospital admissions? A randomized trial in primary care 329
QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study 328
P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion 326
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report 326
Radar-Based Monitoring of Vital Signs: A Tutorial Overview 323
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 319
Cardiac device therapy in patients with left ventricular dysfunction and heart failure: ‘real-world’ data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital) 318
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 318
Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing) 314
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. 312
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA) 312
Clinically guided pacemaker choice and setting: pacemaker expert programming study 307
Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden 305
Implantable cardioverter-defibrillator–computed respiratory disturbance index accurately identifies severe sleep apnea: The DASAP-HF study 303
Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis 301
Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes 300
Meta-analysis of clinical outcomes of electrical cardioversion and catheter ablation in patients with atrial fibrillation and chronic kidney disease 299
Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry 296
Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: a systematic review and meta-analysis 295
Chronic kidney disease and arrhythmias: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference 295
Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples 292
Implant rates of cardiac implantable electrical devices in Europe: A systematic literature review 292
New classification of geometric patterns considering left ventricular volume in patients with chronic aortic valve regurgitation: Prevalence and association with adverse cardiovascular outcomes 292
Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation 291
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 290
The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Executive summary 290
Elevated TGF β2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 288
European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics 285
Heart failure after myocardial revascularization: Risk markers 284
Emery-Dreifuss Muscular Dystrophy-Associated Mutant Forms of Lamin A Recruit the Stress Responsive Protein Ankrd2 into the Nucleus, Affecting the Cellular Response to Oxidative Stress 284
Beta-blocker treatment guided by head-up tilt test in neurally mediated syncope 284
The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden 283
Clinical and electrocardiographic characteristics at admission of COVID-19/SARS-CoV2 pneumonia infection 283
Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. 282
EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation 282
The wearable cardioverter-defibrillator: Current technology and evolving indications 281
Combined use of morphology discrimination, sudden onset, and stability as discriminating algorithms in single chamber cardioverter defibrillators 280
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 280
Atrial fibrillation in dilated cardiomyopathy: Outcome prediction from an observational registry 280
Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF 278
Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA 278
Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry 277
Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation 276
Health economics and the European Heart Rhythm Association. 275
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy 275
New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial 275
A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. 275
Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal 275
Decrease in patient radiation exposure by a tantalum filter during electrophysiological procedures. 273
Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry 273
The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) Randomized Controlled Trial: Phase 1 Results on Dynamics of Early Intervention With Remote Monitoring 272
Letter by Gasparini and Boriani Regarding Article, "Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT)" 270
Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial 270
Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry 270
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. 269
Cardiac resynchronization and implantable cardioverter defibrillator therapy: Preliminary results from the InSync Implantable Cardioverter Defibrillator Italian Registry 269
The QRS interval in patients treated with resynchronization therapy: which value? 268
Far-field R wave oversensing in dual-chamber pacemakers designed for atrial arrhythmia management: effect of pacing site and lead tip to ring distance 268
Management of Phrenic Stimulation in CRT Patients over the Long Term: Still an Unmet Need ? 268
Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE 268
Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations 268
Prediction of cardiac resynchronization therapy response: value of calibrated integrated backscatter imaging. 267
European Society of Cardiology-Proposed Diagnostic Echocardiographic Algorithm in Elective Patients with Clinical Suspicion of Infective Endocarditis: Diagnostic Yield and Prognostic Implications in Clinical Practice 267
Implantable dual-chamber defibrillator for the selective treatment of spontaneous atrial and ventricular arrhythmias: arrhythmia incidence and device performance. 265
Role of ventricular Autocapture function in increasing longevity of DDDR pacemakers: a prospective study. 265
Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy 264
Cardiac resynchronization therapy: effects on left and right ventricular ejection fraction during exercise. 264
Atrial evoked response integral for automatic capture verification in atrial pacing 264
Inappropriate shock for myopotential over-sensing in a patient with subcutaneous ICD 263
Reducing unnecessary right ventricular pacing with the managed ventricular pacing mode in patients with sinus node disease and AV block 263
Totale 51.937
Salva come PNG Salva come JPEG
Categoria #
all - tutte 812.395
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 812.395
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.380 0 0 0 0 0 0 0 0 0 0 1.309 1.071
2021/202215.465 664 1.848 1.677 712 427 1.286 887 786 1.655 1.369 2.411 1.743
2022/202311.536 1.660 974 714 826 1.469 1.536 259 1.187 1.758 206 597 350
2023/20249.853 393 632 435 803 2.283 1.440 447 1.696 223 253 327 921
2024/202533.713 1.151 386 730 1.788 4.911 5.146 3.766 2.148 4.150 2.542 3.045 3.950
2025/202676.503 3.554 1.887 5.259 4.812 5.374 9.122 9.842 3.735 24.539 4.807 3.572 0
Totale 216.794